Find it in seconds.
Sectors Tags Blog
BSX
37 filings
Timeline Columns Start Research 8-K Categories
2025
Q4 4 filings
Nov 19
2026 Annual Bonus Plan and Performance Share Programs Adopted
Awards to certain executive officers under both programs are subject to discretionary recoupment policy
8-K View →
Nov 3
Q3 2025 Results
Financial data not clearly visible in provided XBRL format
10-Q View →
Oct 23
Director John E. Sununu Not Standing for Re-election
John E. Sununu departing 2026 Annual Meeting after 17 years
8-K View →
Oct 22
Q3 Earnings
Q3 2025 financial results for quarter ended Sept 30, 2025
8-K View →
Q3 3 filings
Sep 4
EVP Peripheral Interventions Retired
Jeffrey B. Mirviss retiring Dec 1, 2025, $705K base salary
8-K View →
Aug 1
Q2 2025 Results
Revenue and EPS data not clearly extractable from XBRL format provided
10-Q View →
Jul 23
Q2 Earnings
Q2 2025 financial results announced
8-K View →
Q2 5 filings
May 28
Discontinued ACURATE Valve Systems
Worldwide discontinuation of ACURATE neo2 and Prime Aortic Valve Systems
8-K View →
May 6
2025 Annual Shareholder Meeting Results
All 10 directors elected, say-on-pay approved, simple majority vote proposal passed
8-K View →
May 1
Q1 2025 Results
Unable to extract revenue and EPS - filing contains only XBRL metadata without actual financial values
10-Q View →
Apr 23
Q1 2025 Earnings
Q1 2025 financial results announced
8-K View →
Apr 23
CFO Transition
Daniel Brennan retiring as CFO, Jonathan Monson promoted effective June 30
8-K View →
Q1 6 filings
Mar 19
2025 Proxy Statement
CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled
DEF 14A View →
Feb 26
Euro Debt Offering
€1.5B notes issued (€850M 2031 at 3.0%, €650M 2034 at 3.25%)
8-K View →
Feb 18
FY2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
📌 Multiple strategic acquisitions completed including Silk Road Medical (Sep 2024), Axonics (Nov 2024), and Intera Oncology (Nov 2024)
10-K View →
Feb 12
Director Not Standing for Re-election
Charles J. Dockendorff stepping down after 10 years
8-K View →
Feb 5
Q4 2024 Earnings
Q4 and full year 2024 financial results announced
8-K View →
Jan 16
LOTUS Edge Valve Settlement
Court preliminary approval Jan 8, final hearing Mar 25
8-K View →
2024
Q4 5 filings
Nov 22
2025 Compensation Plans Approved
Annual bonus plan with 0-225% payout range, performance shares with 0-200% range
8-K View →
Nov 15
Acquired Axonics Inc
$3.7B equity value, $71/share cash
8-K View →
Nov 7
Resumed AVANT GUARD Clinical Trial
Trial studying drug-naïve patients with persistent atrial fibrillation resumed after data monitoring committee assessment
8-K View →
Nov 1
Q3 2024 Results
Financial figures not extractable from XBRL metadata provided
10-Q View →
Oct 23
Q3 Earnings
Q3 2024 financial results for quarter ended Sept 30
8-K View →
Q3 3 filings
Aug 1
Q2 2024 Results
Unable to extract revenue and EPS figures from provided XBRL taxonomy data
10-Q View →
Jul 30
New Director Appointed
David C. Habiger appointed to Board, ~$256K prorated compensation
8-K View →
Jul 24
Q2 2024 Earnings
Q2 2024 financial results announced
8-K View →
Q2 5 filings
May 10
New Director Appointed & Credit Line Extended
Dr. Cheryl Pegus joins board, $2.75B credit facility extended to 2029
8-K View →
May 6
Annual Shareholder Meeting
9 directors elected, bylaws amended for proxy rules
8-K View →
May 1
Q1 2024 Results
Unable to extract revenue and EPS figures from provided XBRL data
10-Q View →
Apr 24
Q1 Earnings
Q1 2024 financial results for quarter ended March 31, 2024
8-K View →
Apr 4
Current Report
8-K View →
Q1 6 filings
Feb 27
Current Report
8-K View →
Feb 20
Annual Report
10-K View →
Jan 31
Current Report
8-K View →
Jan 31
Current Report
8-K View →
Jan 8
Current Report
8-K View →
Jan 8
Current Report
8-K View →
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.